

Table S1. Sequence alignment of influenza-LEAPS conjugated peptides.

Influenza A Protein: HA		HA1															
LEAPS Sequence HA1: DLLKNGERIEKVEGGGLKSTQNAIDEITNKVN Sequence used in LEAPS Conjugate		Position															
		L	K	S	T	Q	N	A	I	D	E	I	T	N	K	V	N
		38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53
AAM75158		A/Puerto Rico/8/34/Mount Sinai (H1N1)		Q	N	G	
ACP44189		A/California/07/2009(H1N1)		
ACQ55359		A/California/07/2009(H1N1)		
ABW90127		A/Viet Nam/1203/2004(H5N1)		K	E	.	.	.	K	.	.	G	V	.	.	.	
AAW80717		A/Viet Nam/1203/2004(H5N1)		K	E	.	.	.	K	.	.	G	V	.	.	.	

Influenza A Protein: HA		HA2												
LEAPS Sequence HA2: DLLKNGERIEKVEGGGLFGAIAGFIEGG Sequence used in LEAPS Conjugate		Position												
		G	L	F	G	A	I	A	G	F	I	E	G	G
		1	2	3	4	5	6	7	8	9	10	11	12	13
AAM75158		A/Puerto Rico/8/34/Mount Sinai (H1N1)	
ACP44189		A/California/07/2009(H1N1)	
ACQ55359		A/California/07/2009(H1N1)	
ABW90127		A/Viet Nam/1203/2004(H5N1)	
AAW80717		A/Viet Nam/1203/2004(H5N1)	

Influenza A Protein: NP		NP														
LEAPS Sequence NP: DLLKNGERIEKVEGGGNATYQRTRALVRTG Sequence used in LEAPS Conjugate:		Position														
		N	D	A	T	Y	Q	R	T	R	A	L	V	R	T	G
		144	145	146	147	148	149	150	151	152	153	154	155	156	157	158
AAM75159		A/Puerto Rico/8/34/Mount Sinai (H1N1)		
AAM94596		A/Puerto Rico/8/34/Mount Sinai (H1N1)		
ACP44183		A/California/07/2009(H1N1)		
ACS94534		A/California/07/2009(H1N1)		
AAT70630		A/Viet Nam/1203/2004(H5N1)		
AAW80720		A/Viet Nam/1203/2004(H5N1)		
ADN78224		A/Bethesda/NIH107-D31/2009 #		
KC885957		A/Zhejiang/DTID-ZJU01/2013(H7N9)		

Note: Oseltamivir resistant pH1N1

Influenza A Protein: M2e		M2e																						
LEAPS Sequence M2e: DLLKNGERIEKVEGGGSLLTEVETPIRNEWGSRNSDSSD Sequence used in LEAPS Conjugate:		Position																						
		S	L	L	T	E	V	E	T	P	I	R	N	E	W	G	S*	R	S*	N	D	S	S	D
		2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
ACP41955		A/California/07/2009(H1N1)		T	.	S	.	.	E	.	.	.	S	
ACP44185		A/California/07/2009(H1N1)		T	.	S	.	.	E	.	.	.	S	
ACP44171		A/California/07/2009(H1N1)		T	.	S	.	.	E	.	.	.	S	
ABP35634		A/Viet Nam/1203/2004(H5N1)		T	E	.	.	.	S	
AAT70528		A/Viet Nam/1203/2004(H5N1)		T	E	.	.	.	S	
ADN78223		A/Bethesda/NIH107-D31/2009 #		T	.	S	.	.	E	.	.	.	S	
KC853764		A/Hangzhou/1/2013(H7N9)		T	.	T	G	.	E	.	N	.	S	G	.	.	E	
KC885959		A/Zhejiang/DTID-ZJU01/2013(H7N9)		T	.	T	G	.	E	.	N	.	S	G	.	.	E	

Note: Oseltamivir resistant pH1N1

* Changed to S for increased peptid stability and to avoid formation of inter an intra disulfide bonds.




Fig. S1. Phenotypic characterization of murine bone marrow derived DCs (BMDCs). A representative phenotype of BMDCs from at least 3 independent experiments; isotype control (■) and specific cell surface markers (—).





Fig. S2. Cell surface markers on the surface of BMDCs upon stimulation with influenza-conjugated LEAPS. Representative BMDCs phenotype upon influenza-LEAPS stimulation from at least 3 independent experiments; isotype control (■) and non-pulsed DCs, immature DCs (.....) and pulsed DCs (—)

A.



B.




Fig. S3 Cell surface markers on the surface of BMDCs A) High levels of CD86 expression on MHC II⁺ DCs B) CD86 expression on BMDCs upon stimulation with combined, M2e, NP, HA1 and HA2 conjugated LEAPS; isotype control (■) and pulsed DCs (—)




Fig. S4 LEAPS-loaded DCs in whole blood. 10^7 CFSE labeled combined LEAPS stimulated DCs were injected I.V. into naïve (A) or influenza (PR8) virus infected mice (10LD_{50} , PR8 virus, I.N.)(B). The number of CFSE positive cells was measured in whole blood 24 h post-administration of CFSE- combined LEAPS stimulated DCs. The data are representative FACS plots from each group (n=5 mice/group).

A.




Fig. S5 Activation of endogenous DCs following LEAPS treatment. Representative FACS plots from naïve (A) or 10LD₅₀ influenza virus (PR8) infected (B) mice received CFSE labeled combined LEAPS pulsed DCs. At 24 h post-administration, the mice were sacrificed and their lungs analyzed by flow cytometry for CFSE⁻ CD11c⁺MHC II⁺CD86⁺ DCs.




Fig. S6. DCs loaded with influenza-LEAPS reduce morbidity and mortality in pH1N1 virus infected mice. Mice were infected intranasally with 10^7 TCID₅₀ of A/California/07/2009. Twenty-four hours later, mice were treated with combined-LEAPS conjugated or non-specific peptide conjugated-LEAPS pulsed DCS. Percent survival, p < 0.01 log-rank (Mantel-Cox) test (A), % change in body weight (B) and virus titer in the lungs of infected mice harvested 4 days post-infection are presented; p=0.001 Student's *t* test (C).